Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.38 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23530012 | 0.92 | PIM1 (0.38) | P2RX3P2RX2XDH | |
| SCHEMBL30791991 | 0.78 | XDH (0.44) | MCHR1P2RX3P2RX2XDHGRM4 | |
| SCHEMBL23554540 | 0.78 | XDH (0.44) | MCHR1P2RX3P2RX2XDHGRM4 | |
| SCHEMBL23530040 | 0.77 | SLC5A2 (0.42) | P2RX3P2RX2 | |
| SCHEMBL23530302 | 0.76 | POLB (0.41) | CNR2 | |
| SCHEMBL29549714 | 0.74 | SLC5A2 (0.48) | P2RX3P2RX2 | |
| SCHEMBL23554570 | 0.74 | SLC5A2 (0.48) | P2RX3P2RX2 | |
| SCHEMBL1928108 | 0.71 | MCHR1 (0.42) | MCHR1XDHGRM4GRM5 | |
| SCHEMBL518065 | 0.71 | CHRNB2 (0.48) | XDHGRM4 | |
| SCHEMBL28044526 | 0.70 | MAPT (0.51) | XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4079734-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-10-26 | — | — | EP | disclosed |
| CN-114302886-A | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2022-04-08 | — | — | CN | disclosed |
| WO-2021121294-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
| CN-112979655-A | Triazolopyridazine derivative, preparation method, pharmaceutical composition and application thereof | 上海赛默罗生物科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | MCHR1 4263/4885P2RX3 242/4885P2RX2 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.